Real-world anti-EGFR therapy in elderly mCRC patients: A monocentric analysis stratified by comorbidity and polypharmacy.

Journal of Clinical Oncology 2026 Open access

Read full text
Authors: Chiara Cataldi, Arianna Sabatini, Mattia Alberto Di Civita, Elisabetta Bengala, Camilla Capasso, Adele Artemi, Fabio Ciurluini, Elisa Tramontano, Camilla Bonanni, Luca Zacco, Martina Straffi, Giorgia Pustorino
+2 more Vincenzo Picone, D Santini
DOI: 10.1200/jco.2026.44.2_suppl.67
Cited by: 0

Abstract

67 Background: Elderly patients with metastatic colorectal cancer (mCRC) are increasingly encountered in clinical practice and often undertreated. While anti-EGFR monoclonal antibodies are standard in RAS wild-type disease, their feasibility in frail individuals is not fully characterized. Real-world data remain limited. Methods: We retrospectively reviewed patients aged ≥70 years with RAS/BRAF wild-type mCRC treated with anti-EGFR therapy at our center from Jan 2018 to Dec 2024. Baseline variables included age, sex, ECOG PS, comorbidities, and concomitant medications. Patients were stratified into low burden (

Fields of Study & Subjects

Colorectal Cancer Treatments and Studies Colorectal Cancer Surgical Treatments Frailty in Older Adults

Publication details

Journal / source
Journal of Clinical Oncology
Volume
44
Issue
2_suppl
Pages
67–67
Publication date
10 January 2026
Language
EN